Shares of Jounce Therapeutics Inc (NASDAQ:JNCE) have been given an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.
Brokers have set a 12-month consensus price objective of $29.00 for the company and are forecasting that the company will post ($0.59) EPS for the current quarter, according to Zacks. Zacks has also assigned Jounce Therapeutics an industry rank of 181 out of 265 based on the ratings given to related companies.
JNCE has been the topic of several research reports. Robert W. Baird reissued a “buy” rating and set a $30.00 price target on shares of Jounce Therapeutics in a research note on Friday, November 10th. JPMorgan Chase & Co. set a $28.00 target price on shares of Jounce Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th. Finally, Zacks Investment Research raised shares of Jounce Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 15th.
Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings results on Monday, November 13th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.12. The firm had revenue of $18.10 million for the quarter, compared to the consensus estimate of $20.00 million. Jounce Therapeutics had a negative net margin of 2.03% and a negative return on equity of 1.39%. The firm’s revenue for the quarter was up 7.1% compared to the same quarter last year. analysts anticipate that Jounce Therapeutics will post -0.86 EPS for the current fiscal year.
In related news, Director Barbara Gayle Duncan sold 4,000 shares of Jounce Therapeutics stock in a transaction on Friday, January 26th. The shares were sold at an average price of $25.00, for a total value of $100,000.00. Following the transaction, the director now directly owns 4,000 shares of the company’s stock, valued at $100,000. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Several hedge funds and other institutional investors have recently modified their holdings of JNCE. BlackRock Inc. increased its stake in shares of Jounce Therapeutics by 60.1% in the fourth quarter. BlackRock Inc. now owns 1,161,840 shares of the company’s stock worth $14,812,000 after buying an additional 436,114 shares during the period. Fosun International Ltd increased its stake in shares of Jounce Therapeutics by 208.8% in the third quarter. Fosun International Ltd now owns 285,960 shares of the company’s stock worth $4,455,000 after buying an additional 193,350 shares during the period. Brown Advisory Inc. increased its stake in shares of Jounce Therapeutics by 55.9% in the third quarter. Brown Advisory Inc. now owns 475,719 shares of the company’s stock worth $7,411,000 after buying an additional 170,661 shares during the period. Vanguard Group Inc. increased its stake in shares of Jounce Therapeutics by 123.8% in the second quarter. Vanguard Group Inc. now owns 255,060 shares of the company’s stock worth $3,578,000 after buying an additional 141,096 shares during the period. Finally, Alyeska Investment Group L.P. boosted its holdings in Jounce Therapeutics by 43.7% in the third quarter. Alyeska Investment Group L.P. now owns 262,105 shares of the company’s stock valued at $4,084,000 after acquiring an additional 79,683 shares in the last quarter. 47.47% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Jounce Therapeutics Inc (JNCE) Given $29.00 Consensus Price Target by Brokerages” was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/12/jounce-therapeutics-inc-jnce-given-29-00-consensus-price-target-by-brokerages.html.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.